- Reuters•50 minutes ago
French drugmaker Sanofi reported higher-than-expected first-quarter profits on Friday, buoyed by its specialty care division Genzyme, by vaccines, and by consumer products acquired from Germany's Boehringer ...
- PR Newswire•1 hour ago
Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA
TARRYTOWN, N.Y. and PARIS, April 28, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi today announced that the U.S. Food and Drug Administration has accepted the resubmission of the Biologics License Application for Kevzara (sarilumab) as a Class I response with a two month review timeline. Kevzara is an investigational human monoclonal antibody directed against the IL-6 receptor being evaluated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), such as methotrexate. The companies recently received a positive opinion for Kevzara from the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), and the European Commission (EC) is expected to make a final decision on the Marketing Authorization Application (MAA) for Kevzara in the European Union in the coming months.
- Motley Fool•17 hours ago
Is it time for Amgen to spend some of its cash stockpile? The big biotech's Q1 results say "yes."
SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||46.42 - 46.92|
|52 Week Range||36.81 - 46.92|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||24.27|
|Dividend & Yield||1.58 (3.46%)|
|1y Target Est||N/A|